Navinci Diagnostics AB announces closing of SEK 90M Series A financing, led by Segulah Medical Acceleration with support from existing shareholders

UncategorizedLeave a comment

Navinci Diagnostics AB, a Swedish life science company developing innovative tools for spatial proteomics research, announces the closing of a SEK 90 million financing round. The round was led by Segulah Medical Acceleration (”SMA”), a Scandinavia-based life science-focused investment company, together with existing shareholders, including Landegren Gene Technology AB, Nexttobe AB, and Beijer Ventures AB.…

Naveni pY PD1 – new in situ kit for detection of phosphorylated PD1!

UncategorizedLeave a comment

Navinci has developed several in situ Proximity Ligation Assays, providing deep biological knowledge about the signaling pathways of PD1 and PD-L1. The first assay available to order is: Naveni pY PD1 (phosphorylated PD1) PD1 PD-L1 signaling has proven significant in cancer progression, and therapies with immune checkpoint inhibitors have revolutionized cancer treatment efficacy. Despite the…

Shows the specific localization of ACE 2 with NaveniFlex

The importance of specific protein detection in ACE2 localization studies

Uncategorized

Correct localization of proteins is critical for both the understanding and treatment of many diseases. High specificity immunoassays are of particular value for precision diagnostics use and in large-scale therapeutics development. The quality of these in situ protein detection assays depends mainly on the antibodies’ specificity against the target. Many commercial antibodies have low specificity,…

Detect phosphorylation with NaveniFlex proximity ligation

Uncategorized

Protein phosphorylation has been the target of many drugs, both approved and under development, as well as diagnostics. Phosphorylation status lies beyond the capability of transcriptomics or genomics and is commonly addressed with antibody-based techniques. Most commercially available phospho-antibodies show a moderate-to-high lack of both specificity and sensitivity in immunostainings. It results in generating false-positive…